论文部分内容阅读
目的探讨噻托溴铵治疗稳定期慢性阻塞性肺疾病(COPD)患者的临床疗效。方法将88例稳定期COPD患者随机分为观察组和对照组,每组44例。在常规治疗基础上,对照组行异丙托溴铵治疗,雾化吸入,80μg/次,3次/d;观察组行噻托溴铵治疗,雾化吸入,18μg/次,1次/d;两组均连续治疗16周。检测两组治疗前后的肺功能指标,采用免疫比浊法检测血清血清超敏C反应蛋白(hs-CRP)、ELISA法检测肿瘤坏死因子-α(TNF-α)。结果治疗前,两组用力肺活量、第1秒用力肺活量、第1秒用力呼气容积占预计值百分比比较差异均无统计学意义(P均>0.05);治疗后,两组各指标均高于治疗前,以观察组为著(P均<0.05)。治疗前,两组血清hs-CRP和TNF-α水平差异均无统计学意义(P均>0.05);治疗后,两组上述各指标均降低,以观察组为著(P均<0.05)。观察组口干、头晕、恶心、心悸等不良反应的总发生率为6.81%,对照组为9.09%,两组差异无统计学意义(P>0.05)。结论噻托溴铵治疗稳定期COPD的临床疗效显著,且安全。
Objective To investigate the clinical efficacy of tiotropium in patients with stable chronic obstructive pulmonary disease (COPD). Methods 88 patients with stable COPD were randomly divided into observation group and control group, 44 cases in each group. On the basis of routine treatment, the control group was treated with ipratropium bromide, inhalation, 80μg / time, 3 times / d; observation group treated with tiotropium, atomization inhalation, 18μg / time, 1 / ; Two groups were treated for 16 weeks. The indexes of lung function before and after treatment were detected. Serum hs-CRP was detected by immunoturbidimetry and tumor necrosis factor-α (TNF-α) by ELISA. Results Before treatment, there were no significant differences in forced vital capacity, forced expiratory volume in 1 second and forced expiratory volume in 1 second in percentage of predicted value (all P> 0.05). After treatment, the indexes of both groups were higher than Before treatment, the observation group (P <0.05). Before treatment, there was no significant difference in serum hs-CRP and TNF-α levels between the two groups (all P> 0.05). After treatment, the above indexes of both groups were decreased, and the observation group was the same (all P <0.05). The total incidence of adverse reactions such as dry mouth, dizziness, nausea and palpitations was 6.81% in the observation group and 9.09% in the control group, with no significant difference between the two groups (P> 0.05). Conclusion The clinical efficacy of tiotropium in the treatment of stable COPD is significant and safe.